TCWP’s Regeneron Pharmaceuticals REGN Stock Holding History

TCWP’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-117	Closed	-$81K	–	1398
2022 Q1	$81K	Buy	+117	New	+$74K	0.01%	393

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

TCWP's REGN Position: Q2 2022 in Review

TCWP sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 117 shares — an estimated $81K sold.

TCWP first reported a position in REGN in Q1 2022 and held it in 1 quarter. The position peaked at $81K in Q1 2022. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

TCWP reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
TCWP sold 117 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $81K.
TCWP first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 1 quarter.
TCWP's Regeneron Pharmaceuticals position peaked at $81K in Q1 2022.
1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on TCWP's 13F filing for Q2 2022, filed 15 Aug 2022.